patent.fyi
Applications  /  US 2026/0356807
United States Patent Application Publication

US 2026/0356807 A1

Published
Nov 12, 2026
Filed
Jun 26, 2026
Earliest date on the face
Nov 27, 2018
Classification
C07D 231/56
First published here
Nov 20, 2026

Generated automatically. Not reviewed by a person. Not legal advice or an opinion.

Section 1 · machine-generated

What if?

Questions about how individual parts of claim 1 might be changed. A question may describe something different from what the claim language recites, or a version of it; no view is offered on which.

1.1Direct sigma receptor modulation

What ifWhat if a single-site ligand modulates sigma-1 receptor activity through direct binding?
Claim language“a bifunctional compound”

A tetrahydroindazole ligand occupies the sigma-1 receptor binding pocket and modulates receptor activity through occupancy. Ligand concentration controls occupancy at a fixed receptor abundance.

1.2Recruit a RING finger ligase

What ifWhat if the ligase-binding moiety recruits the RING finger protein RNF114?
Claim language“selected from VHL, cereblon, MDM2, IAP E3 ligase”

A cysteine-reactive recruiter attaches covalently to RNF114 and carries a tethered sigma receptor ligand. The tether brings the recruited ligase near the bound receptor and positions its associated ubiquitin-conjugating enzyme for transfer to accessible lysines.

1.3Assemble through peptide pairing

What ifWhat if two separately prepared ligand conjugates assemble through noncovalent peptide pairing?
Claim language“chemically linked to the ULM and the PTM”

The ligase binder and the receptor binder each attach to one member of a complementary pair of coiled-coil peptides. In a reconstituted assay, the peptides form a heterodimer that holds the two binders together through hydrophobic packing and ionic contacts.

1.4Use a phenylpiperidine binding group

What ifWhat if a phenylpiperidine supplies the sigma receptor binding group?
Claim language“a compound described by compound described by Formulas I, II, III, IV”

The receptor-binding scaffold is 4-phenyl-1-(4-phenylbutyl)piperidine. The protonatable piperidine nitrogen supplies a basic center, and the two phenyl groups provide hydrophobic contacts in the receptor pocket.

1.5Use an oxygen ring atom

What ifWhat if an oxygen atom occupies the variable ring position in a morpholine-based sigma-1 binding group?
Claim language“X is either CH or Nitrogen”

In 2-(morpholin-4-yl)ethyl 1-phenylcyclohexane-1-carboxylate, the morpholine oxygen occupies the ring position opposite the basic nitrogen. The nitrogen supplies the protonatable center, and the phenylcyclohexyl group supplies the hydrophobic portion of the ligand.

Section 2 · machine-generated

Variations

Further arrangements of the same subject matter, described here as of the publication date at the foot of this page.

Other field of use

Reference perturbation for imaging assay development

Use a tetrahydroindazole conjugate with a cereblon-binding group as a reference perturbation in the development of cell imaging assays. Apply the conjugate, the unconjugated receptor ligand, and vehicle to separate wells of a culture plate. Fix the cells, stain for the selected sigma receptor and nuclei, and compare per-cell receptor fluorescence with receptor abundance measured by immunoblotting.

Component substitution

DCAF15 recruitment through an aryl sulfonamide

Replace the ligase-binding group with an aryl sulfonamide that recruits the DCAF15 ubiquitin ligase complex. Join an aryl sulfonamide derivative and a tetrahydroindazole receptor ligand through a flexible linker, using attachment positions that retain binding to each protein. Measure ligase binding and receptor binding separately, then compare receptor abundance in parental cells and cells depleted of DCAF15.

Parameter or scale variation

Linker length series with fixed binding groups

Prepare four conjugates with the same tetrahydroindazole ligand and cereblon-binding group joined by linkers containing 2, 4, 6, or 8 ethylene glycol units. Keep both attachment positions and terminal amide connections fixed across the series. Expose cells to 0.03, 0.3, and 3 micromolar of each conjugate for 4 and 24 hours, then measure receptor abundance and viable cell count.

Combination with existing systems

Receptor turnover in a perfused cell chip

Integrate a tetrahydroindazole conjugate with a perfused microfluidic culture chip containing receptor-expressing cells in parallel channels. Perfuse one channel with conjugate and a second with vehicle, then switch both channels to compound-free medium. Fix replicate channels at the end of exposure and at successive washout times, then quantify receptor staining per cell to measure depletion and recovery.

Receptor selectivity profiling by targeted proteomics

Couple a tetrahydroindazole conjugate exposure assay to targeted liquid chromatography–tandem mass spectrometry. Treat cells that express both sigma receptors, isolate a membrane-enriched fraction, and digest its proteins with trypsin. Add stable-isotope-labeled peptide standards for unique peptides from each receptor and quantify the endogenous peptides against their standards. Report abundance changes for both receptors alongside a membrane protein recovery control.

Automated or data-driven variant

Automated concentration and time response profiling

Use a robotic liquid handler to dispense serial dilutions of each conjugate into replicate plates seeded with receptor-expressing cells. Stagger dosing so all plates reach their assigned exposure times at one collection point, then fix and stain for the receptor and nuclei. Segment cells from the nuclear images, normalize receptor fluorescence to vehicle wells on each plate, and fit concentration-response curves for each exposure time. Flag wells with low cell counts so declines in cell number remain visible alongside changes in receptor signal.

Specific version of a part

Glutarimide cereblon recruiter

A glutarimide-containing moiety binds cereblon through its cyclic imide group. An exocyclic amino group on the adjoining aromatic ring provides an attachment point for the linker.

Triethylene glycol diamide linker

A triethylene glycol-derived spacer carries an amide at each end. One amide connects the spacer to the ligase-binding moiety, and the other connects it to the receptor-binding moiety.

Nitrogen at the variable position

A ring nitrogen occupies X in the receptor-binding scaffold. The nitrogen replaces the carbon and its attached hydrogen at that position and supplies a lone pair.

Methyl at the R4 position

A methyl group occupies R4 on the receptor-binding scaffold. The substituent adds one carbon and presents a small hydrophobic surface at that site.

Section 3 · quoted from USPTO records

Other work

Passages reproduced word for word from two earlier-published U.S. patent documents, placed beside the language of claim 1. No characterization is offered. Each passage is marked A or B for the document it comes from; ¶ numbers are the paragraph numbers in the USPTO’s published full text of that document.

Document AUS 2018/0215731 A1
Published
Aug 2, 2018
Filed
Jan 31, 2018
Class
C07D 401/14
Document BUS 2018/0256586 A1
Published
Sep 13, 2018
Filed
Dec 13, 2017
Class
A61K 31/529
Claim 1
Document A
Document B
1.1a bifunctional compound of chemical structure: ULM-L-PTM
In an additional aspect, the disclosure provides bifunctional or PROTAC compounds, which comprise an E3 Ubiquitin Ligase binding moiety (i.e., a ligand for an E3 Ubiquitin Ligase or “ULM” group), and a moiety that binds a target protein (i.e., a protein/polypeptide targeting ligand or “PTM” group) such that the target protein/polypeptide is placed in proximity to the ubiquitin ligase to effect degradation (and inhibition) of that protein.
A · US 2018/0215731 A1 · ¶ 15
In certain embodiments, the compound comprises an ILM or a VLM or a CLM or a MLM coupled, e.g., linked covalently, directly or indirectly, to a moiety that binds a target protein (i.e., a protein targeting moiety or a “PTM”). In certain embodiments, the ILM/VLM/CLM/MLM and PTM are joined or coupled via a chemical linker (L).
B · US 2018/0256586 A1 · ¶ 65
1.2wherein ULM is a small molecule ubiquitin ligase binding moiety selected from VHL, cereblon, MDM2, IAP E3 ligase binding moiety binding moiety
In certain aspects, the present disclosure provides compounds which comprise a ligand, e.g., a small molecule ligand (i.e., having a molecular weight of below 2,000, 1,000, 500, or 200 Daltons), which is capable of binding to a ubiquitin ligase, such as IAP, VHL, MDM2, or cereblon.
A · US 2018/0215731 A1 · ¶ 30
1.3wherein L is a bond or a chemical linker that is chemically linked to the ULM and the PTM
In another embodiment, the present disclosure is directed to a compound which comprises a PTM group, which binds to a target protein or polypeptide, which is ubiquitinated by an ubiquitin ligase and is chemically linked directly to the ULM group (such as CLM) or through a linker moiety L, or PTM is alternatively a ULM′ group (such as CLM′) which is also a ubiquitin ligase binding moiety, which may be the same or different than the ULM group as described above and is linked di
A · US 2018/0215731 A1 · ¶ 178
1.4wherein PTM is a compound described by compound described by Formulas I, II, III, IV, V, or VI: including pharmaceutically acceptable salts, solvates, and/or prodrugs thereof
Such small molecule target protein binding moieties also include pharmaceutically acceptable salts, enantiomers, solvates and polymorphs of these compositions, as well as other small molecules that may target a protein of interest.
A · US 2018/0215731 A1 · ¶ 192
1.5wherein X is either CH or Nitrogen
1.6wherein R1 is selected from wherein R2 is selected from Hydrogen
1.7wherein R3 is selected from wherein R4 is Hydrogen or methyl
R26 of OR26 is an optionally substituted alkyl, wherein the optional substituents are OH, halogen or NH2; and m is an integer from 1-8, R3 and R4 of Formula (XXVII) and (XXVIII) are independently selected from an optionally substituted alkyl, optionally substituted cycloalkyl, optionally substituted aryl, optionally substituted arylalkyl, optionally substituted arylalkoxy, optionally substituted heteroaryl, optionally substituted heterocyclyl, optionally substituted heteroary
B · US 2018/0256586 A1 · ¶
1.8wherein if the compound is described by Formula I then R2 cannot be

An empty cell means only that no passage was reproduced there.

Statements in these documents
The bifunctional compounds are useful as modulators of targeted ubiquitination, especially with respect to a variety of polypeptides and other proteins, which are degraded and/or otherwise inhibited by bifunctional compounds according to the present disclosure.
A · US 2018/0215731 A1 · ¶ 3
On the other hand, protein-protein interactions are notoriously difficult to target using small molecules due to their large contact surfaces and the shallow grooves or flat interfaces involved.
A · US 2018/0215731 A1 · ¶ 4
The bifunctional compounds are useful as modulators of targeted ubiquitination of FLT3 (and mutants thereof), which is degraded and/or otherwise inhibited by bifunctional compounds according to the present disclosure.
B · US 2018/0256586 A1 · ¶ 4
On the other hand, protein-protein interactions are notoriously difficult to target using small molecules due to their large contact surfaces and the shallow grooves or flat interfaces involved.
B · US 2018/0256586 A1 · ¶ 5
Cite aspatent.fyi, US 2026/0356807 A1, claim 1, first published 2026-11-20T07:31:16-05:00, https://patent.fyi/US20260356807/, SHA-256 52a478df2ba140cb36a4e9811fcf7a08a007f607ed5b8f731ffe8ff5ddcae037
First published
Permanent addresshttps://patent.fyi/US20260356807/
Content fingerprint (SHA-256)52a478df2ba140cb36a4e9811fcf7a08a007f607ed5b8f731ffe8ff5ddcae037
Methodv2026-11-18.2 · automated, not reviewed by a person
Correctionscorrections@patent.fyi